Evidence map›Paper›PMID 40525275›Full record

ArticleMolecular oncology2025

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing.

Navit Mooshayef, Hana Barhom, Sumit Chatterji, Netta Hecht, Oran Warhaftig, Iris Kamer, Oranit Zadok, Jair Bar, Limor Broday, Amir Onn and 1 more

Abstract read
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Navit MooshayefInstitute of Pulmonary Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel.
Hana BarhomFaculty of Medical & Health Sciences, Tel Aviv University, Israel.
Sumit ChatterjiInstitute of Pulmonary Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel.
Netta HechtFaculty of Medical & Health Sciences, Tel Aviv University, Israel.
Oran WarhaftigFaculty of Medical & Health Sciences, Tel Aviv University, Israel.
Iris KamerInstitute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel.
Oranit ZadokInstitute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel.
Jair BarFaculty of Medical & Health Sciences, Tel Aviv University, Israel.
Limor BrodayDepartment of Cell and Developmental Biology, Faculty of Medical & Health Sciences, Tel Aviv University, Israel.
Amir OnnInstitute of Pulmonary Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel.
Michael PeledInstitute of Pulmonary Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel.ORCID 0000-0002-7567-577X

Funding

Alrov FundFlight Attendants Medical Research Institute (FAMRI), Florida, USAIsrael Innovation Authority 81420Israel Innovation Authority 81421The G. Baum Fund - Pulmonary and TB Tel-Aviv Clinic
6 · The paper itself

Abstract

Non-small cell lung cancer treatment decisions rely on several diagnostic steps. Tests that rely on DNA sequencing often fail to capture the full mutational landscape of tumor cells, and drug sensitivity testing (DST) has limitations hindering widespread use currently. One of the major challenges for DST is the rapid isolation of a sufficient number of live tumor cells that would allow testing of multiple drugs simultaneously. To address this challenge, we have developed a DST procedure specifically tailored for tumor cells originating from malignant pleural effusions. We first identified tumor cells by anti-epithelial cell adhesion molecule (EpCAM) flow cytometry and then compared several methods for tumor cell isolation: immunomagnetic enrichment of epithelial cells using EpCAM, negative selection via immunomagnetic CD45

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungCell SeparationLung NeoplasmsPleural Effusion, MalignantCell Line, TumorDrug Screening Assays, AntitumorEpithelial Cell Adhesion MoleculeFlow CytometryHumansLeukocyte Common AntigensAntineoplastic AgentsEpithelial Cell Adhesion MoleculeLeukocyte Common AntigensCD45drug sensitivity testingEpCAMlung cancerpleural effusiontumor cell isolation

Identifiers

PMID40525275
PMCPMC12420342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.